SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point Laboratories’ arm completes new Oncology facility in Kakkalur

27 Mar 2024 Evaluate

Caplin Point Laboratories’ wholly owned subsidiary -- Caplin One Labs has completed its state-of-the-art Oncology facility at Kakkalur, near Chennai, and immediate commencement of operations. The total investment commitment for this facility is Rs 150 crore, funded entirely from internal accruals. To start with, the unit will focus on manufacturing a range of Oral Solid Dosage Oncology products, with the Injectable division to commence operations in the next few months. The company plans to expand the portfolio to over 50 oncology products progressively. 

The facility will manufacture tablets (both coated & uncoated), capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment. Initially, these oncology products will be targeted at Latin American countries, leveraging Caplin Group's established presence in these markets. 

In the medium term, Caplin One Labs aims to launch these oncology products in regulated markets such as the US, EU, Mexico, and others. The facility's compliance with USFDA standards from the outset is expected to streamline the approval process, ensuring swift market entry and availability of these critical treatments to patients worldwide. Caplin Group remains dedicated to advancing healthcare solutions, improving patient outcomes, and making a positive impact on communities globally.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1772.50 6.05 (0.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×